Drug Discovery - Pre-clinical Studies

Redx says in vivo data indicates potential of ROCK2 in fibrosis treatment

UK based biotech company Redx said that its lead selective ROCK2 compound has been shown to have broad potential in the treatment of fibrosis as per new in vivo data.

Nash’s NASH NP-160 shows repeated positive results in second pre-clinical study

Nash Pharmaceuticals, a subsidiary of Breathtec Biomedical, has announced that its lead compound for non-alcoholic steatohepatitis (“NASH”) NP-160 showed repeated positive results in a recently completed study investigating its therapeutic effects in the widely used STAM mouse model from SMC Laboratories.

Redx expects to start first-in-man studies with RXC006 during 2020

UK-based Redx Pharma said it expects to start first-in-man studies with RXC006 during 2020 as the first pre-clinical data of the drug candidate has suggested that the compound has great potential as a fibrosis treatment.

Cyxone MS drug T20K succeeds in preclinical program

Cyxone said that T20K, its investigational drug for the treatment of multiple sclerosis (MS), has succeeded in a preclinical program by yielding positive results in the toxicology studies.

Scientists engineer DNA-encoded monoclonal antibodies targeting Zaire Ebolavirus

Scientists at The Wistar Institute and collaborators have engineered novel DNA-encoded monoclonal antibodies (DMAbs) targeting Zaire Ebolavirus that were effective in preclinical models.

Inovio develops DNA-encoded monoclonal antibody checkpoint inhibitor

Inovio Pharmaceuticals said that it has completed animal testing of DNA-encoded monoclonal antibodies targeting the immune checkpoint molecule CTLA-4.

Scientists discover potential druggable target for lung cancer treatment

Scientists in the UK claim to have identified a crucial molecular player in a subtype of lung cancer that could pave way for a new approach towards treating the condition.

Study finds new drug treatment could reduce liver transplants

Scientists in the UK believe that patients with sudden liver failure could benefit from a new treatment in the future that could cut down the need for transplants by preventing a process called senescence with certain anti-cancer therapy drugs.

Oxford BioMedica forms three-way partnership for cystic fibrosis treatment

Oxford BioMedica has collaborated with the UK Cystic Fibrosis Gene Therapy Consortium (GTC) and Imperial Innovations for the development of a long-term therapy to treat patients with cystic fibrosis.